Skip to content
DataLookout
Menu

TroFuse-031NCT07419295

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 31 versions: 30 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 111 → 117 locations
  2. Minor Study sites: 111 to 113
  3. Minor Trial sites expanded: 107 → 111 locations
  4. Minor Trial sites expanded: 104 → 107 locations
  5. Minor Study sites: 104 to 105
  6. Minor Trial sites expanded: 95 → 104 locations
  7. Minor Study sites: 94 to 95
  8. Notable Eligibility criteria expanded, about 30 words
    • Trial sites expanded: 91 → 94 locations
    • Secondary endpoints: details revised at 11 of 11 entries
  9. Minor Study sites: 90 to 91v23
  10. Minor Trial sites expanded: 86 → 90 locationsv22
  11. Minor Trial sites expanded: 82 → 86 locationsv21
  12. Minor Study sites: 80 to 82v20
  13. Minor Study sites: 79 to 80v19
  14. Minor Trial sites expanded: 73 → 79 locationsv18
  15. Minor Study sites: 71 to 73v17
  16. Minor Study sites: 69 to 71v16
  17. Minor Study sites: 67 to 69v15
  18. Minor Study sites: 65 to 67v14
  19. Minor Study sites: 63 to 65v13
  20. Notable Eligibility criteria expanded, about 15 words
    • Trial sites expanded: 50 → 63 locations
    v12
  21. Minor Trial sites expanded: 42 → 50 locationsv11
  22. Minor Trial sites expanded: 38 → 42 locationsv10
  23. Minor Trial sites expanded: 30 → 38 locationsv9
  24. Minor Trial sites expanded: 27 → 30 locationsv8
  25. Minor Trial sites expanded: 21 → 27 locationsv7
  26. Minor Trial sites expanded: 3 → 21 locations
    • Start date changed from estimate of Apr 30, 2026 to Apr 23, 2026
    v6
  27. Minor Start date: Apr 15, 2026 to Apr 30, 2026v4
  28. Minor Study sites: 2 to 3v3
  29. Notable Recruitment opened
    • Study sites: 0 to 2
    • Start date: Mar 17, 2026 to Apr 15, 2026
    v2
  30. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival (OS)
Timeframe: Up to approximately 40 months

Secondary (11)

Progression-Free Survival (PFS)
Objective Response Rate (ORR)
Duration of Response (DOR)
Number of Participants Who Experience an Adverse Event (AE)
Number of Participants Who Discontinue Study Treatment Due to an AE
Show 6 moreShow less
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Change From Baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Change From Baseline in EORTC QLQ-C30 Fatigue (Items 10, 12, and 18) Combined Score
Change From Baseline in EORTC QLQ-C30 Nausea/Vomiting (Items 14 and 15) Combined Score
Change From Baseline in EORTC QLQ-C30 Diarrhea (Item 17) Score

Arms and interventions

Sacituzumab tirumotecanExperimental

Participants receive 4 mg/kg of sacituzumab tirumotecan every 2 weeks (Q2W) via intravenous (IV) infusion until disease progression or unacceptable toxicity.

ChemotherapyActive comparator

Participants receive paclitaxel 175 mg/m\^2, docetaxel 75 mg/m\^2, or vinflunine 320 mg/m\^2 IV every 3 weeks (Q3W), at the investigator's discretion, until disease progression or unacceptable toxicity.

Biologicals: Sacituzumab tirumotecan

Drugs: Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy

Sites

117 sites in 17 countries

United States 23, China 20, Japan 16, Italy 9, Spain 8, Netherlands 7, Greece 5, Israel 5, Argentina 4, Belgium 4, Brazil 4, Canada 3, Australia 2, France 2, Sweden 2, United Kingdom 2, Germany 1